The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists

Published 2021 View Full Article

Authors

Keywords

chronic kidney disease, DAPA-CKD, dapagliflozin, hyperkalemia, mineralocorticoid receptor antagonists, sodium–glucose cotransporter-2 inhibitor

Journal

Kidney International Reports

Volume -, Issue -, Pages -

Publisher

Elsevier BV

Online

2021-12-14

DOI

10.1016/j.ekir.2021.12.013

References

View 12 related references

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now